Hexarelin: Uses, Dosing, Safety, and How It Compares to Related Peptides

What Hexarelin Is and How It Works

Hexarelin (also spelled hexarelin acetate) is a six-amino-acid analogue of growth hormone-releasing peptide-6 (GHRP-6). It binds the growth hormone secretagogue receptor type 1a (GHSR-1a) in the pituitary and hypothalamus, triggering a dose-dependent GH pulse that is among the largest recorded for any synthetic secretagogue. A secondary receptor, CD36 (a scavenger receptor expressed on cardiac and vascular cells), mediates effects on the heart that appear to be entirely independent of GH release [1].

The GH pulse hexarelin produces differs from the continuous GH elevation seen with exogenous recombinant GH. Because it works through an endogenous pulsatile pathway, IGF-1 rises more physiologically, though IGF-1 elevation is still meaningful. In a crossover study published in the European Journal of Endocrinology, Arvat et al. showed that 2 mcg/kg IV hexarelin produced a mean GH peak of approximately 70 mIU/L in healthy adults, compared to roughly 20 mIU/L for GHRH alone [2].

Hexarelin also releases prolactin and ACTH at pharmacologic doses, which is one reason dosing precision matters. Those hormonal side-paths are attenuated at the 1 mcg/kg range used in most body-composition protocols.

Clinical Evidence: Where the Data Actually Stand

Three areas have the strongest published support: GH deficiency, cardiac ischemia protection, and body composition in older adults.

GH deficiency. A 1997 study by Ghigo et al. (Journal of Clinical Endocrinology and Metabolism) tested hexarelin in 24 adults with hypopituitarism. The peptide still produced significant GH release even in patients with partial somatotroph function, suggesting that residual pituitary reserve, not just hypothalamic GHRH tone, determines the response [3]. The authors noted that "hexarelin may be useful as a diagnostic tool in assessing residual GH secretory capacity."

Cardioprotection. Muccioli et al. demonstrated in isolated rat heart preparations that hexarelin reduced infarct size by roughly 30% vs. vehicle when administered before ischemia-reperfusion injury. The protective effect persisted after hypophysectomy (removal of the pituitary), confirming the CD36 pathway rather than GH as the mediator [4]. Human cardiac trials remain at the Phase I/II stage; no large RCT has been completed as of this writing.

Body composition. A 2001 trial by Mericq et al. (Pediatric Research) in GH-deficient children showed that six months of subcutaneous hexarelin (2 mcg/kg twice daily) produced growth velocity and IGF-1 increases comparable to those seen with recombinant GH at standard doses [5]. Adult body-composition data are largely from open-label or preclinical work. The tachyphylaxis problem, described below, limits the duration of measurable effect.

Dosing Protocols: What the Research Supports

Research protocols vary, but two ranges dominate the literature.

For diagnostic GH stimulation: a single IV bolus of 2 mcg/kg, with GH measured at 0, 15, 30, 45, and 60 minutes. Peak response typically arrives at 15 to 30 minutes.

For longer-term body-composition or recovery applications in clinical research: 1 to 2 mcg/kg subcutaneous once or twice daily, with a documented desensitization period. Three to four weeks of daily dosing produces measurable tachyphylaxis at the pituitary GHSR-1a receptor. A study by Ghigo et al. showed that GH response to hexarelin fell to roughly 50% of baseline after four weeks of continuous daily administration, and recovered substantially after a two-week washout [6].

Because of this pattern, most research-based protocols cycle hexarelin for four to six weeks on, two weeks off. Stacking with a GHRH analogue such as CJC-1295 may partially offset receptor downregulation by hitting a distinct receptor upstream, though head-to-head cycling data in humans are limited.

Oral bioavailability is poor (below 1% in most animal models). Subcutaneous injection remains the standard route in all published human work.

Safety and Side Effects

Hexarelin's side-effect profile is better characterized than most research peptides because it was studied in formal dose-escalation trials in the 1990s and early 2000s.

Elevated cortisol and prolactin are the most reproducible adverse findings at doses above 2 mcg/kg. Arvat et al. recorded a mean cortisol increase of approximately 60 nmol/L above baseline at the 2 mcg/kg IV dose, which is meaningful but well below the range associated with clinical hypercortisolism [2].

Water retention and transient hunger (via ghrelin-receptor cross-reactivity) are reported anecdotally in clinical practice and are consistent with GHSR-1a agonism. Fatigue immediately post-injection is common and likely reflects the mild cortisol and prolactin spikes.

Cardiovascular safety data are reassuring in short-term human trials. No arrhythmias or significant QTc changes were recorded in a 14-day hexarelin infusion study reviewed in the European Journal of Endocrinology [7]. Long-term cardiovascular data in humans do not exist.

Hexarelin is not approved by the FDA for any indication. Under the agency's 2024 guidance on bulk drug substances, hexarelin is not on the list of permitted compounding substances for Section 503A or 503B pharmacies. Patients obtaining it outside a supervised clinical research context carry real regulatory and quality-control risk [8].

Epitalon: The Telomere-Associated Tetrapeptide

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from epithalamin, a polypeptide extract of the bovine pineal gland. Its claimed mechanism centers on activation of telomerase (hTERT), which could theoretically slow telomere attrition in dividing cells.

The primary published evidence comes from Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation. One study in Bulletin of Experimental Biology and Medicine (2003) reported that epitalon increased telomerase activity in human fetal fibroblasts and extended mean cell passage number [9]. The data are interesting but have not been independently replicated in large human trials. No Phase III RCT exists.

Animal longevity studies, including a 2014 paper by Khavinson et al. in Advances in Gerontology, showed up to 13% lifespan extension in mice given epitalon over their lifetime vs. controls. Translating rodent longevity data to humans is unreliable without mechanistic replication studies. Epitalon shares hexarelin's FDA compounding restrictions and has no approved human indication anywhere in the world.

MOTS-c: Mitochondria-Derived Peptide and Metabolic Regulation

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded in the mitochondrial genome, not the nuclear genome. That origin makes it biologically distinct from every synthetic peptide on this list.

The key mechanism: MOTS-c activates AMPK (AMP-activated protein kinase), the same pathway targeted by metformin, and reduces insulin resistance by increasing glucose uptake in skeletal muscle. In a landmark 2015 Cell Metabolism paper, Lee et al. showed that intraperitoneal MOTS-c (5 mg/kg daily for 14 days) prevented diet-induced obesity and reversed insulin resistance in mice fed a high-fat diet. Fasting glucose fell by approximately 30% vs. vehicle-treated controls [10].

Human data are sparse. One observational study found that circulating MOTS-c levels decline with age in humans, with a median plasma concentration of roughly 150 pg/mL in adults aged 20, 30 vs. roughly 90 pg/mL in adults aged 60, 80, providing a rationale for exogenous supplementation in older populations [11]. No completed Phase II/III trials in humans appear in the ClinicalTrials.gov registry as of early 2025.

Exercise appears to increase endogenous MOTS-c. A paper in Nature Communications (2022) documented significant plasma MOTS-c elevation after acute aerobic exercise in healthy adults, suggesting that some of its metabolic benefit may be mimicked by training [12].

SS-31: Cardiolipin-Targeting Mitochondrial Protective Peptide

SS-31 (elamipretide; D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane by binding cardiolipin, a phospholipid essential to the electron transport chain. By stabilizing cardiolipin, SS-31 reduces reactive oxygen species (ROS) production and preserves mitochondrial membrane potential under stress conditions.

SS-31 has the most advanced clinical pipeline of any peptide in this group. Stealth BioTherapeutics ran it through a Phase III trial (MMPOWER-3, N=218) in Barth syndrome, a rare mitochondrial cardiomyopathy. At 48 weeks, elamipretide 40 mg/day subcutaneous did not meet its primary endpoint (distance on the 6-minute walk test), but secondary endpoints including left ventricular mass and patient-reported fatigue showed meaningful improvement [13].

A separate Phase II trial in heart failure with preserved ejection fraction (HFpEF) reported that four weeks of SS-31 infusion improved left ventricular diastolic function (E/e' ratio reduction of approximately 1.8 units vs. placebo, P<0.05) in 47 participants [14]. HFpEF represents a real unmet clinical need, and the mitochondrial mechanism is biologically plausible given the documented mitochondrial dysfunction in that population.

Subcutaneous dosing of 40 mg/day was well tolerated in Phase III work, with injection-site reactions as the most common adverse event (reported in 34% of the elamipretide group vs. 18% placebo).

Humanin: The Cytoprotective Mitochondria-Encoded Peptide

Humanin is a 21-amino-acid peptide also encoded in the mitochondrial 12S rRNA region, making it a close genomic neighbor of MOTS-c. Its primary actions are antiapoptotic: humanin binds the proapoptotic protein BAX, prevents cytochrome c release, and activates JAK2/STAT3 signaling in neurons and cardiomyocytes.

The original discovery of humanin (Hashimoto et al., 2001, PNAS) showed it protected neurons from Alzheimer's-related amyloid beta (Abeta25-35) toxicity at nanomolar concentrations in cell culture [15]. That finding launched substantial interest in its potential for neurodegeneration.

Circulating humanin declines markedly with age. A study in the Journal of Clinical Endocrinology and Metabolism (Muzumdar et al., 2009) reported that serum humanin immunoreactivity was approximately 40% lower in adults over 70 compared with adults aged 20, 40, and correlated inversely with markers of insulin resistance [16]. IGF-1 suppresses humanin expression in a feedback loop, which complicates protocols that simultaneously target GH/IGF-1 and humanin.

In rodent models, humanin improved spatial memory in Alzheimer's mouse models, reduced atherosclerotic plaque area by approximately 35% in ApoE-knockout mice, and extended mean lifespan by roughly 12% in C. elegans overexpression studies [17]. No completed RCT in humans has been published. Human Phase I safety work has not been indexed on PubMed as of this writing.

A synthetic analogue, HNG (Humanin with Gly14 substitution), shows 1,000-fold greater potency than native humanin in cell-culture neuroprotection assays, which means very low doses may eventually be testable in humans without the pharmacokinetic challenges of the native peptide.

Hexarelin vs. GHRP-6 and Ipamorelin: Where It Sits in the Secretagogue Class

Growth hormone secretagogues are not interchangeable. Understanding the differences helps clinicians select the right tool.

GHRP-6 is structurally similar to hexarelin but produces a notably larger ghrelin-receptor-driven hunger response and more pronounced cortisol/prolactin release. Hexarelin produces a stronger acute GH pulse than GHRP-6 at equivalent molar doses, as documented in a head-to-head comparison by Deghenghi et al. [18].

Ipamorelin is the cleanliness choice. It produces minimal cortisol and prolactin release even at high doses, making it better tolerated for longer cycles, but its peak GH pulse is lower than hexarelin's. A study comparing 1 mcg/kg doses of ipamorelin, GHRP-2, and hexarelin found mean GH peaks of approximately 22, 40, and 68 mIU/L, respectively, in healthy adults [19].

The CD36 cardiac receptor that hexarelin activates is not bound by ipamorelin or GHRP-6. That makes hexarelin uniquely interesting for cardiac indications, though clinical human data for that application remain preliminary.

Regulatory Status and Access in 2025

The FDA's 2024 action on bulk drug substances for compounding effectively removed hexarelin, along with BPC-157, TB-500 fragment, and several other peptides, from the list of substances 503A and 503B pharmacies may compound [8]. Patients who were on these protocols through licensed telehealth providers were required to transition or discontinue.

Epitalon, MOTS-c, SS-31, and humanin face similar or identical restrictions depending on their clinical development stage. SS-31 (elamipretide) is furthest along in formal drug development and may eventually receive FDA approval for a specific indication if ongoing trials succeed.

Purchasing any of these peptides from unregulated online vendors bypasses pharmaceutical-grade quality control entirely. Contamination, incorrect dosing, and mislabeling have all been documented in independent testing of gray-market peptide products.

Clinicians prescribing within a research context or under an IND (Investigational New Drug) application retain legal routes to access these compounds. Patients interested in these therapies should seek providers who work within IRB-approved research protocols or who can document a clear clinical rationale under existing compounding law.